PMID- 20523093
OWN - NLM
STAT- MEDLINE
DCOM- 20101025
LR  - 20181201
IS  - 1423-0240 (Electronic)
IS  - 0378-584X (Linking)
VI  - 33
IP  - 6
DP  - 2010
TI  - Evaluation of treatment with bosentan in patients with carcinoid heart disease: 
      single center study.
PG  - 300-4
LID - 10.1159/000313596 [doi]
AB  - BACKGROUND: The primary aim of this study was to evaluate a combined therapeutic 
      intervention, including the dual endothelin receptor antagonist bosentan, in 
      patients with carcinoid heart disease (CaHD). The efficacy of the treatment 
      protocol was investigated using serological, echocardiographic, and clinical 
      markers. PATIENTS AND METHODS: Since 2003, 40 patients with neuroendocrine 
      tumours were identified; 14 had echocardiographic findings consistent with CaHD. 
      Six of the 14 patients with CaHD and a New York Heart Association (NYHA) 
      functional class >or= III received bosentan and were eligible for inclusion in 
      this study. RESULTS: N-terminal pro-brain natriuretic peptide (NT-pro-BNP) had 
      decreased 6 months after treatment with bosentan (median: 646 pg/ml vs. 400.5 
      pg/ml; p = 0.02); the right ventricular systolic pressure had decreased after 3 
      and 6 months (median: 69 mmHg vs. 61 mmHg, p = 0.02; median: 69 mmHg vs. 48.5 
      mmHg, p = 0.02); the 6-minute walk distance (6MWD) had significantly improved 
      after 3 and 6 months of treatment (median: 293.5 vs. 406.5 m; p = 0.02; median: 
      293.5 vs. 578.5 m; p = 0.02). The NYHA functional class improved in 5/6 patients 
      receiving bosentan. CONCLUSIONS: Combined treatment with bosentan is effective in 
      patients with CaHD, based on functional class, 6MWD, and NT-pro-BNP. Further 
      clarification of the CaHD fibrosis pathogenesis is needed to facilitate 
      development of targeted antifibrotic therapeutic agents.
FAU - Lafaras, Christos T
AU  - Lafaras CT
AD  - Theagenion Cancer Hospital, Thessaloniki, Greece. iatros@the.forthnet.gr
FAU - Mandala, Eudokia M
AU  - Mandala EM
FAU - Platogiannis, Dimitrios N
AU  - Platogiannis DN
FAU - Saratzis, Athanasios N
AU  - Saratzis AN
FAU - Barbetakis, Nikolaos G
AU  - Barbetakis NG
FAU - Paraskevopoulos, Panagiotis P
AU  - Paraskevopoulos PP
FAU - Ilonidis, George C
AU  - Ilonidis GC
FAU - Bischiniotis, Theodoros S
AU  - Bischiniotis TS
LA  - eng
PT  - Journal Article
DEP - 20100511
PL  - Switzerland
TA  - Onkologie
JT  - Onkologie
JID - 7808556
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Endothelin Receptor Antagonists)
RN  - 0 (Peptide Fragments)
RN  - 0 (Sulfonamides)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - Q326023R30 (Bosentan)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/adverse effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Bosentan
MH  - Carcinoid Heart Disease/blood/diagnosis/*drug therapy
MH  - Combined Modality Therapy
MH  - Echocardiography, Doppler
MH  - *Endothelin Receptor Antagonists
MH  - Exercise Test/drug effects
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Neoplasms/*drug therapy/pathology
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Ovarian Neoplasms/*drug therapy/pathology
MH  - Peptide Fragments/blood
MH  - Sulfonamides/adverse effects/*therapeutic use
EDAT- 2010/06/05 06:00
MHDA- 2010/10/26 06:00
CRDT- 2010/06/05 06:00
PHST- 2010/06/05 06:00 [entrez]
PHST- 2010/06/05 06:00 [pubmed]
PHST- 2010/10/26 06:00 [medline]
AID - 000313596 [pii]
AID - 10.1159/000313596 [doi]
PST - ppublish
SO  - Onkologie. 2010;33(6):300-4. doi: 10.1159/000313596. Epub 2010 May 11.